- Home
- LRE vs CING Comparison
LRE vs CING Comparison
Compare LRE & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- CING
- Stock Information
- Founded
- LRE 2001
- CING 2012
- Country
- LRE Japan
- CING United States
- Employees
- LRE N/A
- CING N/A
- Industry
- LRE
- CING Biotechnology: Pharmaceutical Preparations
- Sector
- LRE
- CING Health Care
- Exchange
- LRE Nasdaq
- CING Nasdaq
- Market Cap
- LRE 17.6M
- CING 16.2M
- IPO Year
- LRE 2023
- CING 2021
- Fundamental
- Price
- LRE $2.00
- CING $4.36
- Analyst Decision
- LRE
- CING Strong Buy
- Analyst Count
- LRE 0
- CING 4
- Target Price
- LRE N/A
- CING $30.67
- AVG Volume (30 Days)
- LRE 20.0K
- CING 250.6K
- Earning Date
- LRE 07-30-2015
- CING 05-08-2025
- Dividend Yield
- LRE N/A
- CING N/A
- EPS Growth
- LRE N/A
- CING N/A
- EPS
- LRE 0.29
- CING N/A
- Revenue
- LRE $117,804,154.00
- CING N/A
- Revenue This Year
- LRE N/A
- CING N/A
- Revenue Next Year
- LRE N/A
- CING N/A
- P/E Ratio
- LRE $6.62
- CING N/A
- Revenue Growth
- LRE 8.82
- CING N/A
- 52 Week Low
- LRE $1.10
- CING $1.80
- 52 Week High
- LRE $13.76
- CING $20.83
- Technical
- Relative Strength Index (RSI)
- LRE 84.20
- CING 61.94
- Support Level
- LRE $1.86
- CING $3.81
- Resistance Level
- LRE $1.99
- CING $4.09
- Average True Range (ATR)
- LRE 0.12
- CING 0.26
- MACD
- LRE 0.06
- CING 0.07
- Stochastic Oscillator
- LRE 100.00
- CING 96.43
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.